Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells

Emerging evidence suggests that chemotherapeutic agents and targeted anticancer drugs have serious side effects on the healthy cells/tissues of the patient. To overcome this, the use of non-oncology drugs as potential cancer therapies has been gaining momentum. Herein, we investigated one non-oncolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yulu, Sharma, Amit, Ge, Fangfang, Chen, Peng, Yang, Yu, Liu, Hongjia, Liu, Hongde, Zhao, Chunxia, Mittal, Lovika, Asthana, Shailendra, Schmidt-Wolf, Ingo G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235775/
https://www.ncbi.nlm.nih.gov/pubmed/37274234
http://dx.doi.org/10.3389/fonc.2023.1157366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235775/
https://www.ncbi.nlm.nih.gov/pubmed/37274234
http://dx.doi.org/10.3389/fonc.2023.1157366

Ejemplares similares